Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

MAP completes patient enrollment in phase III clinical trial of MAP-0004

Jan. 27, 2009

Glenmark files phase I trial application with MHPRA for GRC-15300

Jan. 26, 2009

FDA approves Geron's IND for phase I clinical trial of GRNOPC-1 in spinal cord injury

Jan. 26, 2009

Cladribine significantly reduced relapse rate of MS in phase III pivotal trial

Jan. 26, 2009

Fenobam safe, affects behavior in patients with Fragile X syndrome

Jan. 26, 2009

Solvay claims novel cannabinoid CB1 receptor agonists for use as analgesic agents

Jan. 26, 2009

Novartis launches Extavia for multiple sclerosis

Jan. 23, 2009

Phase III data support use of NGX-4010 in postherpetic neuralgia

Jan. 23, 2009

Neurologix initiates phase II clinical trial of gene transfer therapy for Parkinson's disease

Jan. 23, 2009

Novel calcitonin gene-related peptide (CGRP) receptor antagonists disclosed by Merck & Co.

Jan. 23, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...